skip to main content

Brain Tumor

Gene therapy for glioma improved survival in early research

A study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.

Study finds better survival for patients with diffuse midline glioma

For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound, called ONC201, nearly doubled survival for patients with diffuse midline glioma or diffuse intrinsic pontine glioma, compared to previous patients.

Rogel awarded SPORE grant designed to further research on radiosensitization

An inter-departmental group of researchers at the Rogel Cancer Center received a grant from the National Cancer Institute to further research on radiosensitization, the process of making tumors more vulnerable to radiation treatment.

Research suggests glioblastomas contain active cells which control growth

Cancerous brain tumor cells may be at ‘critical point’ between order and disorder. Large-scale coordination of brain tumor behavior may allow tumor cells to resist better against therapies such as chemotherapy and radiation, researchers say.

Awake surgery for cancerous brain tumor gives referee new focus

After an awake surgery to remove a cancerous brain tumor, a Michigan man is living “more deliberately” than ever — officiating a high school wrestling state championship and participating in research for a potential cure.

Thrown into Cancer Land

How a caregiver has navigated supporting her mother during brain cancer treatment.

Arificial intelligence speeds up genetic analysis of cancerous brain tumors

Using artificial intelligence, researchers have discovered how to screen for genetic mutations in cancerous brain tumors in under 90 seconds — and possibly streamline the diagnosis and treatment of gliomas, a study suggests.

Kim receives Research Specialist Award from NCI to advance clinical trials

Michelle Kim, M.D., associate professor of radiation oncology at Michigan Medicine, has received a Research Specialist Award from the National Cancer Institute to pursue clinical research efforts at the University of Michigan Rogel Cancer Center and nationally. Kim’s focus is on clinical research for central nervous system (CNS) tumors.

Researchers at Rogel Cancer Center Circumvent Radiation Resistance in Subtype of Brain Tumors

Patients whose brain tumors have a mutated enzyme called IDH1 typically live longer than those without the mutation. But even as these tumors are initially less aggressive, they always come back. A key reason: The tumors are resistant to radiation treatment and are invasive.